home.aspx
 
EVENTS

The Digital Pharma Advances
THE DIGITAL PHARMA ADVANCES
January 29-29, 2020
Powerfully Target & Engage HCPs & Patients & Deliver Real-World Results With Integrated, Innovative Digital Strategies.Customer-Centric, Value-Adding, Multi-Channel Digital Pharma Marketing Strategies.

4th Annual Microbiome Movement, Drug Development, Europe
4TH ANNUAL MICROBIOME MOVEMENT, DRUG DEVELOPMENT, EUROPE
February 04-05, 2020
As the first microbiome-based therapeutic steps closer to market approval, the scientific community continue to demonstrate the functional role of the human microbiome as a novel source of therapeutic, biomarker and diagnostic development. Despite this progress, the vast potential to develop effecti...

Bluepharma

SHARESHARESHARE
Bluepharma is today one of the most entrepreneurial and innovative groups in the pharmaceutical industry, enjoying remarkable prestige at the national level and in the most demanding international markets. Through its 18 subsidiaries, the activity of Bluepharma covers the entire drug value chain, from R&D to the market, acknowledged for the excellence of the production unit, the quality and qualifications of its employees and the experience and dynamics of the management team.
SHARESHARESHARE

RELATED NEWS


Genetic alterations in low-risk prostate cancer diagnosed by needle biopsy can identify men that harbor higher-risk cancer in their prostate glands, according to new research reported in the January edition of Mayo Clinic Proceedings. This study is the first to report that genetic alteration associated with intermediate- and high-risk prostate cancer also may be present in some cases of low-risk prostate cancers. The study found the needle biopsy procedure may miss higher-risk cancer that increa...

READ MORE

With the sale of its controversial rare-disease drug finalized, Marathon Pharmaceuticals has taken the unusual step of resigning from the powerful industry lobbying group PhRMA....

READ MORE

As researchers struggle to find a treatment for Alzheimer’s disease, the field struggles with the difficulties of early diagnosis. There are a number of biomarkers identified that show a tendency toward the disease, such as ApoE, but not definitive tests. Researchers with the German Center for Neurodegenerative Diseases (DZNE) may have found one. Scientists at DZNE, the Hertie Institute for Clinical Brain Research (HIH) and the University Hospital Tuebingen identified a protein in blood th...

READ MORE

The growth in the US market has fallen to 9 per cent in the first half of 2016-17 and is expected to be under further pressure in the future.Greater regulatory checking, consolidation of the supply chain resulting in pricing pressure as well rise in R&D expenses are ,however, impacting the profitability of Indian pharmaceutical companies....

READ MORE

The US Food and Drug Administration (FDA) rejected Akcea and Ionis’ application for the use of Waylivra in the treatment of familial chylomicronemia syndrome (FCS) despite the earlier support of expert advisers. Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals received a Complete Response Letter (CRL) from the Division of Metabolism and Endocrinology Products of the FDA rejecting the application for Waylivra (volanesorsen). Paula Soteropoulos, the chief executive officer of Akcea ...
PIOTR WNUK
READ MORE

Pharmacists should not sell cannabis-derived medical products over the counter (OTC), according to pharmacy students at the 2019 Annual Professional Debate. Co-hosted by the Royal Pharmaceutical Society (RPS) in Wales and Healthcare Education and Improvement Wales (HEIW) Pharmacy  eanery, this year’s debate was held in Cardiff on 8 April 2019. During the evening, more than 100 pharmacy students debated whether pharmacies should supply OTC medical cannabis products. After hearing argum...
THE PHARMACEUTICAL JOURNAL
READ MORE

EVENTS

The Digital Pharma Advances
THE DIGITAL PHARMA ADVANCES
January 29-29, 2020
Powerfully Target & Engage HCPs & Patients & Deliver Real-World Results With Integrated, Innovative Digital Strategies.Customer-Centric, Value-Adding, Multi-Channel Digital Pharma Marketing Strategies.

4th Annual Microbiome Movement, Drug Development, Europe
4TH ANNUAL MICROBIOME MOVEMENT, DRUG DEVELOPMENT, EUROPE
February 04-05, 2020
As the first microbiome-based therapeutic steps closer to market approval, the scientific community continue to demonstrate the functional role of the human microbiome as a novel source of therapeutic, biomarker and diagnostic development. Despite this progress, the vast potential to develop effecti...